Tumors of the Central Nervous System: 2 Tumors of the Central Nervous System, Volume 2
Glioblastoma
(Sprache: Englisch)
This wide-ranging survey of the field examines a plethora of relevant material, covering issues as diverse as the advantages and limitations of biomarkers in gliomagenesis to the diagnostic applications of imaging methodologies such as PET and SPECT.
Leider schon ausverkauft
versandkostenfrei
Buch (Gebunden)
Fr. 401.90
inkl. MwSt.
- Kreditkarte, Paypal, Rechnungskauf
- 30 Tage Widerrufsrecht
Produktdetails
Produktinformationen zu „Tumors of the Central Nervous System: 2 Tumors of the Central Nervous System, Volume 2 “
This wide-ranging survey of the field examines a plethora of relevant material, covering issues as diverse as the advantages and limitations of biomarkers in gliomagenesis to the diagnostic applications of imaging methodologies such as PET and SPECT.
Klappentext zu „Tumors of the Central Nervous System: 2 Tumors of the Central Nervous System, Volume 2 “
Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients with high-grade gliomas is clarified. The advantage of the use of intraoperative low-field MRI in glioma surgery is explained.
Inhaltsverzeichnis zu „Tumors of the Central Nervous System: 2 Tumors of the Central Nervous System, Volume 2 “
Chapter 1. INTRODUCTIONI. BIOMARKERS AND DIAGNOSIS
Chapter 2. GLIOMAGENESIS: ADVANTAGES AND LIMITATIONS OF BIOMARKERS
Chapter 3. MOLECULAR SUBTYPES OF GLIOMAS
Chapter 4. GLIOBLASTOMA: GERMLINE MUTATION OF TP5
Chapter 5. GLIOMAS: ROLE OF THE TP53 GENE
Chapter 6. THE ROLE OF IDH1 AND IDH2 MUTATIONS IN MALIGNANT GLIOMAS
Chapter 7. MALIGNANT GLIOMA: ISOCITRATE DEHYDROGENASES 1 AND 2 MUTATIONS
Chapter 8. METABOLIC DIFFERNCES IN DIFFERENT REGIONS OF GLIOMA SAMPLES
Chapter 9. GLIOBLASTOMA PATIENTS: ROLE OF METHYLATED MGMT
Chapter 10. BRAIN TUMOR ANGIOGENESIS AND GLIOMA GRADING: ROLE OF TUMOR BLOOD VOLUME AND PERMEABILITY ESTIMATES USING PERFUSION CT
Chapter 11. VASCULOGENIC MIMICRY IN GLIOMA
Chapter 12. NEWLY DIAGNOSED GLIOMA: DIAGNOSIS USING POSITRON EMISSION TOMOGRAPHY WITH METHIONINE AND FLUOROTHYMIDINE
Chapter 13. ROLE OF DIFFUSION TENSOR IMAGING IN DIFFERENTIATION OF GLIOBLASTOMAS FROM SOLITARY BRAIN METASTASES
Chapter 14. I-TM-601 SPECT IMAGING OF HUMAN GLIOMA
Chapter 15. ASSESSMENT OF BIOLOGICAL TARGET VOLUME USING POSITRON EMISSION TOMOGRAPHY IN HIGH-GRADE GLIOMA PATIENTS
Chapter 16. SKIN METASTASES OF GLIOBLASTOMA
II. THERAPY
Chapter 17. DIFFUSE LOW-GRADE GLIOMAS. WHAT DOES "COMPLETE RESECTION" MEAN?
Chapter 18. QUANTITATIVE APPROACH OF THE NATURAL COURSE OF DIFFUSE LOW-GRADE GLIOMAS
Chapter 19. IMPACT OF RESECTION EXTENT ON OUTCOMES IN PATIENTS WITH HIGH-GRADE GLIOMAS
Chapter 20. RECURRENT MALIGNANT GLIOMAS: 5-AMINOLEVULINIC ACID FLUORESCENCE-GUIDED RESECTION
Chapter 21. GLIOMA SURGERY: INTRAOPERATIVE LOW FIELD MAGNETIC RESONANCE IMAGING
Chapter 22. LOW-GRADE GLIOMAS: INTRAOPERATIVE ELECTRICAL STIMULATIONS
Chapter 23. MALIGNANT GLIOMAS: PRESENT AND FUTURE THERAPEUTIC DRUGS
Chapter 24. RECURRENT MALIGNANT GLIOMA PATIENTS: TREATMENT WITH CONFORMAL RADIOTHERAPY AND SYSTEMIC THERAPY
Chapter 25. GLIOBLASTOMA: BORON NEUTRON CAPTURE THERAPY
Chapter 26. GLIOBLASTOMA:
... mehr
ANTI-TUMOR ACTION OF CYCLOSPORINE A AND FUCTIONALLY RELATED DRUGS.
Chapter 27. GLIOBLASTOMA PATIENTS: CHEMOTHERAPY WITH CISPLATIN, TEMOZOLOMIDE AND THALIDOMIDE
Chapter 28. GLIOBLASTOMA : ROLE OF GALECTIN- 1 IN CHEMORESISTANCE
Chapter 29. GLIOMA-INITIATING CELLS: INTERFERON TREATMENT
Chapter 30. GLIOBLASTOMA : ANTITUMOR ACTION OF NATURAL AND SYNTHETIC CANNABINOIDS
Chapter 31. PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: THERAPY WITH COMBINATION OF BEVACIZUMAB AND IRINOTECAN
Chapter 32. MONITORING GLIOMAS IN VIVO USING DIFFUSION- WEIGHTED MRI DURING GENE THREAPY -INDUCED APOPTOSIS
Chapter 33. HIGH-GRADE GLIOMAS: DENDRITIC CELL THERAPY
Chapter 34. GLIOBLASTOMA MULTIFORME: USE OF ADENOVIRAL VECTORS
Chapter 35. FISCHER-F98 GLIOMA MODEL: METHODOLOGY
Chapter 36. CELLULAR CHARACTERIZATION OF ANTI-VEGF AND IL-6 THERAPY IN EXPERIMENTAL GLIOMA
Chapter 37. ADULT BRAINSTEM GLIOMAS: DIAGNOSIS AND TREATMENT
Chapter 38. USE OF LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASE IN GLIOMA PATIENTS
III. PROGNOSIS
Chapter 39. BRAINSTEM GLIOMAS: AN OVERVIEW
Chapter 40. TUMOR-ASSOCIATED EPILEPSY IN PATIENTS WITH GLIOMA
Chapter 41. CHRONIC EPILEPSY ASSOCIATED WITH BRAIN TUMORS: SURGICAL NEUROPATHOLOGY
Chapter 42. LOW-GRADE GLIOMAS: ROLE OF RELATIVE CEREBRAL BLOOD VOLUME IN MALIGNANT TRANSFORMATION
Chapter 43. ANGIOCENTRIC GLIOMA- INDUCED SEIZURES: LESIONECTOMY
Chapter 27. GLIOBLASTOMA PATIENTS: CHEMOTHERAPY WITH CISPLATIN, TEMOZOLOMIDE AND THALIDOMIDE
Chapter 28. GLIOBLASTOMA : ROLE OF GALECTIN- 1 IN CHEMORESISTANCE
Chapter 29. GLIOMA-INITIATING CELLS: INTERFERON TREATMENT
Chapter 30. GLIOBLASTOMA : ANTITUMOR ACTION OF NATURAL AND SYNTHETIC CANNABINOIDS
Chapter 31. PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: THERAPY WITH COMBINATION OF BEVACIZUMAB AND IRINOTECAN
Chapter 32. MONITORING GLIOMAS IN VIVO USING DIFFUSION- WEIGHTED MRI DURING GENE THREAPY -INDUCED APOPTOSIS
Chapter 33. HIGH-GRADE GLIOMAS: DENDRITIC CELL THERAPY
Chapter 34. GLIOBLASTOMA MULTIFORME: USE OF ADENOVIRAL VECTORS
Chapter 35. FISCHER-F98 GLIOMA MODEL: METHODOLOGY
Chapter 36. CELLULAR CHARACTERIZATION OF ANTI-VEGF AND IL-6 THERAPY IN EXPERIMENTAL GLIOMA
Chapter 37. ADULT BRAINSTEM GLIOMAS: DIAGNOSIS AND TREATMENT
Chapter 38. USE OF LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASE IN GLIOMA PATIENTS
III. PROGNOSIS
Chapter 39. BRAINSTEM GLIOMAS: AN OVERVIEW
Chapter 40. TUMOR-ASSOCIATED EPILEPSY IN PATIENTS WITH GLIOMA
Chapter 41. CHRONIC EPILEPSY ASSOCIATED WITH BRAIN TUMORS: SURGICAL NEUROPATHOLOGY
Chapter 42. LOW-GRADE GLIOMAS: ROLE OF RELATIVE CEREBRAL BLOOD VOLUME IN MALIGNANT TRANSFORMATION
Chapter 43. ANGIOCENTRIC GLIOMA- INDUCED SEIZURES: LESIONECTOMY
... weniger
Bibliographische Angaben
- 2011, 2011., 458 Seiten, Masse: 19,8 x 26,6 cm, Gebunden, Englisch
- Herausgegeben:Hayat, M. A.
- Herausgegeben: M. A. Hayat
- Verlag: Springer Netherlands
- ISBN-10: 9400706170
- ISBN-13: 9789400706170
- Erscheinungsdatum: 03.04.2011
Sprache:
Englisch
Kommentar zu "Tumors of the Central Nervous System: 2 Tumors of the Central Nervous System, Volume 2"
0 Gebrauchte Artikel zu „Tumors of the Central Nervous System: 2 Tumors of the Central Nervous System, Volume 2“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Tumors of the Central Nervous System: 2 Tumors of the Central Nervous System, Volume 2".
Kommentar verfassen